Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more
Nautilus Biotechnology Inc (NAUT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.065x
Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has a cash flow conversion efficiency ratio of -0.065x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.03 Million) by net assets ($169.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nautilus Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nautilus Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nautilus Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iljin HySolus Co Ltd
KO:271940
|
0.008x |
|
Verusa Holding AS
IS:VERUS
|
-0.014x |
|
The Nisshin OilliO GroupLtd.
OTCGREY:NSOMF
|
0.044x |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
-0.422x |
|
KANGWON Co. Ltd
KQ:114190
|
0.077x |
|
Symphony International Holdings Limited
PINK:SYNNF
|
-0.006x |
|
Sintana Energy Inc
OTCQX:SEUSF
|
-0.030x |
|
Taiwan Taxi Co Ltd
TWO:2640
|
0.066x |
Annual Cash Flow Conversion Efficiency for Nautilus Biotechnology Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nautilus Biotechnology Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $208.73 Million | $-59.15 Million | -0.283x | -45.40% |
| 2023-12-31 | $265.35 Million | $-51.71 Million | -0.195x | -33.98% |
| 2022-12-31 | $314.92 Million | $-45.81 Million | -0.145x | -34.76% |
| 2021-12-31 | $363.58 Million | $-39.24 Million | -0.108x | -122.92% |
| 2020-12-31 | $-29.72 Million | $-14.00 Million | 0.471x | +187.98% |
| 2019-12-31 | $18.05 Million | $-9.66 Million | -0.535x | +98.88% |
| 2018-12-31 | $5.00 Million | $-238.30 Million | -47.660x | -- |